+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.

Age: 50Years +All GendersPhase 2Phase 3
71 locations
R

Actively Recruiting

Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.

Age: 18Years +All GendersPhase 2
55 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.

Age: 60Years +All GendersPhase 2Phase 3
104 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a subretinal implant called CPCB-RPE1 in people with advanced dry age-related macular degeneration AMD that includes geographic atrophy involving the fovea. This Phase IIb randomized clinical trial compares the implant to a simulated sham procedure to understand its impact on retinal sensitivity and vision. Participants will be randomly assigned to one of two groups up to 18 participants will receive the CPCB-RPE1 implant through surgery, while up to 6 participants will undergo a sham implantation procedure. The study involves up to 6 surgical implantation sites, with additional sites serving as referral or follow-up locations. During the trial, participants will undergo assessments including retinal sensitivity testing and best-corrected visual acuity measurements, with primary outcomes evaluated one year after implantation. The study includes careful monitoring of vision changes and safety over time, lasting until December 2040, to gather comprehensive data on the implants performance.

Age: 55Years - 90YearsAll GendersPhase 2
5 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a one-time intravitreal injection of SAR446597 in people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This Phase 12, two-part, multicenter study aims to understand how the treatment works and its potential benefits over approximately two years, followed by an additional three-year extended follow-up period. Participants will receive a single injection of SAR446597 into the eye or a sham injection, depending on the study part and dose group. Multiple dose levels of SAR446597 will be tested in different participant cohorts, with some receiving the active treatment and others receiving a sham as a control. Part I is open-label, while Part II involves randomized dosing and sham control groups. During the study, participants will be monitored for treatment side effects, changes in vision, and the size of GA lesions using visual acuity tests and lesion measurements at baseline, one year, and two years. Safety assessments will continue through the extended follow-up phase. The study also tracks serious and non-serious adverse events up to two years after treatment, with a total study duration of about five years per participant.

Age: 60Years +All GendersPhase 1Phase 2
35 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of STL303 in adults with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. GA leads to gradual cell death in the back of the eye, causing blurry or missing central vision spots. This randomized, double-masked, multi-center study aims to find the best dose of STL303 and assess its impact on this eye condition. Participants will be randomly assigned to receive either one of two doses of oral STL303 or a placebo. The study compares these groups to understand how STL303 affects the rate of vision loss and other eye health measures. The treatment period lasts up to 104 weeks, with evaluations continuing through week 108 to monitor safety and disease progression. During the study, participants will undergo regular eye exams, including imaging scans and vision tests, to track changes in their condition. Researchers will measure the reduction in the area of eye damage, retinal sensitivity, and vision-related quality of life. Blood samples will be collected at scheduled visits to analyze how the drug is processed in the body. Participants will also record daily medication use and attend frequent study visits for assessments and safety monitoring. The total trial participation may last several years until study completion in 2029.

Age: 60Years +All GendersPhase 2
56 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
S

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a gene therapy called Ixo-vec Ixoberogene soroparvovec in adults aged 50 years and older who have bilateral neovascular wet age-related macular degeneration nAMD. This Phase 2, single-arm, open-label study focuses on treating the second eye contralateral eye with Ixo-vec, including participants who have previously received the therapy in one eye and those receiving it for the first time. The study aims to understand how well the treatment works and how long its effects last when both eyes are treated at different times. Participants will receive a single intravitreal injection of Ixo-vec in the contralateral eye. The study includes both participants experienced with Ixo-vec and those who are treatment-nave, with dosing designed to evaluate safety and clinical activity including visual and anatomical outcomes. The treatments durability will be assessed over time, along with the need for additional anti-VEGF therapy. The study does not involve a placebo or comparator group and is conducted across multiple centers. During the study, participants will be followed for approximately 5 years to monitor safety, including ocular and non-ocular adverse events, and to evaluate visual acuity and retinal thickness changes. Researchers will also track supplemental aflibercept injections required after treatment. Participants will undergo regular assessments of vision and eye health, and adherence to study procedures will be monitored throughout. The long follow-up period allows evaluation of the gene therapys lasting effects and safety profile in bilateral treatment of nAMD.

Age: 50Years +All GendersPhase 2
12 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy for patients with intermediate to advanced nonexudative age-related macular degeneration AMD. This clinical device trial aims to better understand how this treatment may impact vision in this condition, using a randomized, sham-controlled, and double-masked study design. Participants will receive either active transpalpebral microcurrent therapy or a sham version as a comparator. They will undergo an initial loading treatment regimen followed by seven maintenance treatments spread over 11 months. After completing treatment, participants will continue monthly visits through Month 14, which is three months after the last therapy session, for evaluation and monitoring. During the trial, participants will be monitored closely with monthly visits to assess changes in best corrected visual acuity BCVA from baseline at Months 3 and 6, among other measures. The study includes careful safety monitoring and aims to identify responders to the therapy. Overall participation spans over a year, including treatment and follow-up periods to evaluate the therapys impact and safety.

Age: 60Years +All GendersPhase Not Applicable
13 locations
E

Actively Recruiting

Researchers are studying diabetic retinopathy DR, an eye condition caused by diabetes that damages blood vessels in the retina and can lead to vision loss. This trial evaluates surabgene lomparvovec sura-vec, a gene therapy given as a one-time injection into the suprachoroidal space SCS, aiming to treat non-proliferative DR without center-involved diabetic macular edema CI-DME and prevent vision-threatening events. The study includes Phase 2b, Phase 3, and a bilateral treatment portion with about 576 adult participants across the United States and Puerto Rico. Participants are randomly assigned to receive sura-vec plus prophylactic steroids or sham injections plus artificial tears in one eye during the Phase 2b and Phase 3 portions. Those receiving sham may later cross over to sura-vec treatment. In the bilateral portion, participants receive sura-vec and steroids in both eyes. Each participant receives a single injection per eye. Follow-up continues for up to five years after treatment to monitor outcomes and safety. Throughout the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor the treatments effects and any side effects. Researchers will track diabetic retinopathy severity using the Diabetic Retinopathy Severity Scale DRSS and watch for vision-threatening events. Safety is closely monitored, including eye inflammation and other adverse events, with follow-up extending up to approximately two years for the bilateral portion and five years overall. Participants should expect a higher treatment burden than standard care.

Age: 18Years +All GendersPhase 2Phase 3
40 locations